Abstract
Purpose: The purpose of this amendment is to incorporate newly published literature into the original American Society for Radiation Oncology/American Urological Association Adjuvant and Salvage Radiotherapy After Prostatectomy Guideline and provide an updated clinical framework for clinicians. Methods and Materials: The original systematic review yielded 294 studies published between January 1990 and December 2012. In April 2018, the guideline underwent an amendment and incorporated 155 references that were published between January 1990 and December 2017. Two new key questions were added: one on the use of genomic classifiers and the other on the treatment of oligo-metastases with radiation after radical prostatectomy. Results: A new statement on the use of hormone therapy with salvage radiation therapy (RT) after radical prostatectomy was added, and long-term data were used to update an existing statement on adjuvant RT. The balance of the guideline statements were reaffirmed, and references added to the existing literature base. A discussion on the use of genomic classifiers as a risk stratification tool was added to the future research discussion. No relevant data on oligo-metastases were found. Conclusions: Hormone therapy should be offered to patients who have had radical prostatectomy and who are candidates for salvage RT. Clinicians should discuss possible short- and long-term side effects with patients in addition to the potential benefits of preventing recurrence. The decision to use hormone therapy should be made by the patient and a multidisciplinary team of providers with full consideration of the patient's history, values, preferences, quality of life, and functional status.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 208-213 |
| Number of pages | 6 |
| Journal | Practical Radiation Oncology |
| Volume | 9 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 1 2019 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging
Cite this
Adjuvant and Salvage Radiation Therapy After Prostatectomy : ASTRO/AUA Guideline Amendment, Executive Summary 2018. / Pisansky, Thomas M.; Thompson, Ian M.; Valicenti, Richard K; D'Amico, Anthony V.; Selvarajah, Shalini.
In: Practical Radiation Oncology, Vol. 9, No. 4, 01.07.2019, p. 208-213.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Adjuvant and Salvage Radiation Therapy After Prostatectomy
T2 - ASTRO/AUA Guideline Amendment, Executive Summary 2018
AU - Pisansky, Thomas M.
AU - Thompson, Ian M.
AU - Valicenti, Richard K
AU - D'Amico, Anthony V.
AU - Selvarajah, Shalini
PY - 2019/7/1
Y1 - 2019/7/1
N2 - Purpose: The purpose of this amendment is to incorporate newly published literature into the original American Society for Radiation Oncology/American Urological Association Adjuvant and Salvage Radiotherapy After Prostatectomy Guideline and provide an updated clinical framework for clinicians. Methods and Materials: The original systematic review yielded 294 studies published between January 1990 and December 2012. In April 2018, the guideline underwent an amendment and incorporated 155 references that were published between January 1990 and December 2017. Two new key questions were added: one on the use of genomic classifiers and the other on the treatment of oligo-metastases with radiation after radical prostatectomy. Results: A new statement on the use of hormone therapy with salvage radiation therapy (RT) after radical prostatectomy was added, and long-term data were used to update an existing statement on adjuvant RT. The balance of the guideline statements were reaffirmed, and references added to the existing literature base. A discussion on the use of genomic classifiers as a risk stratification tool was added to the future research discussion. No relevant data on oligo-metastases were found. Conclusions: Hormone therapy should be offered to patients who have had radical prostatectomy and who are candidates for salvage RT. Clinicians should discuss possible short- and long-term side effects with patients in addition to the potential benefits of preventing recurrence. The decision to use hormone therapy should be made by the patient and a multidisciplinary team of providers with full consideration of the patient's history, values, preferences, quality of life, and functional status.
AB - Purpose: The purpose of this amendment is to incorporate newly published literature into the original American Society for Radiation Oncology/American Urological Association Adjuvant and Salvage Radiotherapy After Prostatectomy Guideline and provide an updated clinical framework for clinicians. Methods and Materials: The original systematic review yielded 294 studies published between January 1990 and December 2012. In April 2018, the guideline underwent an amendment and incorporated 155 references that were published between January 1990 and December 2017. Two new key questions were added: one on the use of genomic classifiers and the other on the treatment of oligo-metastases with radiation after radical prostatectomy. Results: A new statement on the use of hormone therapy with salvage radiation therapy (RT) after radical prostatectomy was added, and long-term data were used to update an existing statement on adjuvant RT. The balance of the guideline statements were reaffirmed, and references added to the existing literature base. A discussion on the use of genomic classifiers as a risk stratification tool was added to the future research discussion. No relevant data on oligo-metastases were found. Conclusions: Hormone therapy should be offered to patients who have had radical prostatectomy and who are candidates for salvage RT. Clinicians should discuss possible short- and long-term side effects with patients in addition to the potential benefits of preventing recurrence. The decision to use hormone therapy should be made by the patient and a multidisciplinary team of providers with full consideration of the patient's history, values, preferences, quality of life, and functional status.
UR - http://www.scopus.com/inward/record.url?scp=85067548696&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067548696&partnerID=8YFLogxK
U2 - 10.1016/j.prro.2019.04.008
DO - 10.1016/j.prro.2019.04.008
M3 - Article
C2 - 31051281
AN - SCOPUS:85067548696
VL - 9
SP - 208
EP - 213
JO - Practical Radiation Oncology
JF - Practical Radiation Oncology
SN - 1879-8500
IS - 4
ER -